Oxford BioTherapeutics
  • ABOUT
    • OUR TEAM
    • BOARD OF DIRECTORS
    • INVESTORS
    • OFFICES & LABS
  • PIPELINES
    • INTERNAL PROGRAMS
    • PARTNERED PROGRAMS
  • PARTNERSHIPS
  • OUR SCIENCE
    • IO DISCOVERY PLATFORM >
      • IMMUNE CHECKPOINT TARGETS
      • IO ANTIBODY ENGINEERING
    • OGAP DISCOVERY PLATFORM
    • PUBLICATIONS
  • CAREERS
  • NEWS
    • PRESS RELEASES
    • OBT in the News
  • CONTACT

  Partnered Programs

Externally Partnered Pipeline

Our partnered pipeline includes drug candidates that we have out licensed to leading pharmaceutical and biotechnology companies, including Boehringer Ingelheim and Kite Pharma.

Our partners are developing one or more drug candidates that we discovered using our OGAP® platform.
Picture
​
Program
Program Summary
Indications
Molecule Class
OBT620
A DLL3/CD3 bispecific molecule to treat patients with small cell lung cancer and other neuroendocrine tumors that are positive for DLL3. Currently in phase I clinical trial.
​SCLC and neuroendocrine tumors
CD3
bispecific
OBT624
A bispecific molecule to treat patients with advanced solid tumors.
Advanced solid tumors​
CD3
bispecific
OBT551
Undisclosed molecule in pre-clinical development.
Undisclosed
Undisclosed
Four programs
OBT and Boehringer Ingelheim (BI) are collaborating to discover and validate novel selective tumor targets for BI’s unique T-cell engager, cancer vaccine and oncolytic virus platforms, enabled by OBTs OGAP® discovery. Four further programs enabled by OBTs OGAP® discovery platform are also undergoing validation.
Solid tumors
Undisclosed
OBT700
A novel, first-in-class, immune checkpoint receptor agonist discovered and developed by OBT.  
Solid tumors​
IO mAB
OBT035
An ADC specifically targeting ‘cold’ tumors that cannot be treated with check point inhibitors.​
"Cold" and solid tumors​
​ADC
OBT227
​Novel ADC with strong cancer biology overexpressed in multiple solid tumors. ​
Solid tumors
​ADC
OBT417
Novel ADC with strong cancer biology overexpressed in multiple solid tumors. 
​ Solid tumors​
ADC
​Five programs
​​OBT and ImmunoGen are collaborating to develop novel antibidy drug conjugates coupling targets discovered using OBT's OGAP® discovery platform, with ImmunoGen's ADC linker-payload technology. 
​​Hematological and solid tumors​
​​ADC
​Two programs
​Through this collaboration, OBT will validate up to five novel oncology drug targets, previously identified using OBT’s OGAP® discovery platform, and generate antibodies against these. Kite and Gilead will have the exclusive right to develop and commercialize therapies based on these targets or antibodies.​
​​​Hematological and solid tumors​
​​CAR-T therapy
IO mAB: Immuno-oncology monoclonal antibody; ADC: Antibody drug conjugate; CAR-T therapy: Chimeric antigen receptor T cell therapy

Privacy Policy

Legal Notice

Site Map

© 2017 Oxford BioTherapeutics All Rights Reserved
  • ABOUT
    • OUR TEAM
    • BOARD OF DIRECTORS
    • INVESTORS
    • OFFICES & LABS
  • PIPELINES
    • INTERNAL PROGRAMS
    • PARTNERED PROGRAMS
  • PARTNERSHIPS
  • OUR SCIENCE
    • IO DISCOVERY PLATFORM >
      • IMMUNE CHECKPOINT TARGETS
      • IO ANTIBODY ENGINEERING
    • OGAP DISCOVERY PLATFORM
    • PUBLICATIONS
  • CAREERS
  • NEWS
    • PRESS RELEASES
    • OBT in the News
  • CONTACT